ReviewNature reviews. Drug discovery2010
Key factors in the discovery and development of new antiepileptic drugs.
Review in Nature reviews. Drug discovery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 173 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
173 citing papers in PubMed.
- Distinct impacts of sodium channel blockers on the strength-duration properties of human motor cortex neurons.Epilepsia · 2025Trial
- Systematic Design and Evaluation of Nasal Drug Delivery for Central Nervous System Disease from Experimental to Clinical Application.Pharmaceutics · 2026Review
- Review
- Article
- Review
- Ventral subicular pyramidal neurons contribute to epileptogenesis via anterior thalamic circuit.Communications biology · 2025Article
- Ion dynamics underlying the seizure delay effect of low-frequency electrical stimulation.PLoS computational biology · 2025Article
- P2RX7 Dynamics in CNS Disorders: Molecular Insights and Therapeutic Perspectives.Molecular neurobiology · 2025Review
- Adenosine ANeuropharmacology · 2025Article
- Emerging Role of Tripartite Synaptic Transmission in the Pathomechanism of Autosomal-Dominant Sleep-Related Hypermotor Epilepsy.International journal of molecular sciences · 2025Review
- Article
- Investigation of Anticonvulsant Potential ofInternational journal of molecular sciences · 2025Article
- Mutant zebrafish lacking slc25a22a show spontaneous seizures and respond to the anti-seizure medication valproic acid.Disease models & mechanisms · 2025Article
- Beyond seizures: SCN8A heterozygous mutation presenting with epilepsy and paroxysmal dyskinesia.Annals of medicine and surgery (2012) · 2025Article
- P2X7R antagonism suppresses long-lasting brain hyperexcitability following traumatic brain injury in mice.Theranostics · 2025Article
- Zebrafish-based assessment of luteolin's potential in modulating seizure responses.Frontiers in pharmacology · 2025Article
- Purinergic receptor antagonism reduces interictal discharges and rescues cognitive function in a mouse model of temporal lobe epilepsy.Frontiers in neuroscience · 2025Article
- Isoindoline-1,3-dione Derivatives as Prototypes for Anticonvulsant Drug Discovery.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2025Article
- The Antiepileptic Drug Levetiracetam Inhibits Carbonic Anhydrase:ACS medicinal chemistry letters · 2024Article
- New triazole-based hybrids as neurotropic agents.RSC advances · 2024Article
113 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the early 1990s, many new antiepileptic drugs (AEDs) that offer appreciable advantages in terms of their favourable pharmacokinetics, improved tolerability and lower potential for drug-drug interactions have entered the market. However, despite the therapeutic arsenal of old and new AEDs, approximately 30% of patients with epilepsy still suffer from seizures. Thus, there remains a substantial need for the development of more efficacious AEDs for patients with refractory seizures. Here, we briefly review the emerging knowledge on the pathological basis of epilepsy and how it might best be used in the design of new therapeutics. We also discuss the current approach to AED discovery and highlight some of the unique features of newer models of pharmacoresistance and epileptogenesis that have emerged in recent years.
Indexed as
Identifiers
20043029What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.